Dipeptidyl peptidase-4 (DPP-4) inhibitors, novel antidiabetic drugs, have the ability to control blood glucose by inhibiting the degradation of incretin hormones such as type I glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) without the risk of hypoglycemia or body weight gain [9, 10]. Here, GCG is linked to Hypoglycemia.